Helios Meds Review
Appears to have shut downHelios Meds falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Helios Meds is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
See our top-rated GLP-1 providers →Compounded GLP-1 tirzepatide is priced at $349.97/month, compounded semaglutide at $149.99/month. A provider reviews online, then parcels go out discreetly. Helios operates from Hockessin, Delaware, uses US board-certified physicians and holds LegitScript approval. Its pricing is transparent; a public list of states is not enumerated.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Helios Meds
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Helios Meds at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $149.99/mo
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How Helios Meds scores
Six columns, each one computed from something Helios Meds has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
6.7/10$149.99/month is 21% below the register median of $189 for compounded semaglutide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
5.0/10Where this seller first shows a price is not recorded yet, so the signup is unscored and sits at the midpoint.
Trust & Safety15%
4.0/10does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Helios Meds
Last checked June 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
GLP-1 medications Helios Meds offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Check the price yourself before you pay
Every figure here was read off Helios Meds's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $149.99 a month, within the normal band around this register's $189 median for the same drug and form
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Helios Meds charges
The standing price at Helios Meds is $149.99/month. That sits at the affordable end of what we track.
- Compounded semaglutide — $149.99/month
- Compounded tirzepatide — $349.97/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so Helios Meds is genuinely under the middle rather than merely advertising that it is.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What Helios Meds dispenses
Helios Meds prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product — the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
What we could verify
Helios Meds publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
Helios Meds competes on price and does it without an obvious sacrifice elsewhere: $149.99/month, no warning letter on file, and access that is not unusually restricted.
The Bottom Line
Helios Meds falls below our bar on medical oversight. Read the breakdown below before you give it money.
Where Helios Meds is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Helios Meds review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.